Isai Peimer
Senior Analyst @ Surveyor Capital
Washington, United States
Isai Peimer is a Senior Analyst at Surveyor Capital. He attended The Tuck School of Business at Dartmouth.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Isai Peimer invests in
Stages Isai Peimer invests in
Countries Isai Peimer invests in
Investment Focus
Industry
- Biopharma 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series D 1 (50%)
- Funding Round 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ambit Biosciences
|
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3)inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon. | $50M / Nov 06, 2012 | |
|
Ambit Biosciences
|
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3)inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon. | $30M / Series D / Jun 10, 2011 |
Co-Investors
About Surveyor Capital
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
Surveyor Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Isai Peimer
Senior Analyst
|
|||
Joshua A.W. Mosberg
Analyst
|
|||
Brad Lau
Deputy Chief Operating Officer
|
|||
Daniel Krizek
Portfolio Manager
|
|||
Gerald A. Beeson
Senior Managing Director, Chief Operating Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Isai Peimer invest in?
Isai Peimer invests primarily in Biopharma, Health Care and Biotechnology startups, most often at Series D and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Isai Peimer last invest?
The most recent investment recorded for Isai Peimer closed in Nov 2012. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
